A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
CELGENE

Protocol Number
CC-5013-NHL-008

To Learn More Call
201-510-0910